Sangamo Therapeutics (SGMO) added ~9% in the premarket on Friday after the gene therapy developer said that the U.S. FDA ...
Targeted cancer therapies like CDK4/6, EGFR, VEGFR, and BRAF inhibitors may increase long-term kidney dysfunction risk. Learn ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort.
GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.
Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...
Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline ...
On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin ...
Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...
Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...
FOX 5 Atlanta on MSN
Hoschton woman defies odds, survives stage 4 lung cancer diagnosis
Joanne Cure, 78, survived stage 4 lung cancer after being given two years to live, crediting her faith, determination, and ...
The benefits of SGLT2 inhibitors on kidney disease progression in individuals irrespective of diabetes or albuminuria status ...
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback